SUMMARY ANSWER: Coumestrol promotes cell death in the choriocarcinoma cells by regulating ERK1/2 MAPK and JNK MAPK signaling pathways and through disruption of Ca 2+ and ROS homeostasis.
Introduction
Placentation is an important process for successful maintenance of development of the conceptus by providing oxygen and nutrients from the mother to the fetus and removing waste products from fetal blood (Gude et al., 2004) . Placental development initiates from implantation of the blastocyst via apposition of trophoblast and maternal endometrium. During pregnancy, excessive proliferation and invasion of trophoblast causes gestational trophoblastic diseases (GTD) that may present as a hydatidiform mole, a placental-site trophoblastic tumor, an epithelioid trophoblastic tumor, a choriocarcinoma or an invasive mole (Shih Ie, 2007; Lurain, 2011,) . Among those, choriocarcinomas are the most aggressive GTD with abnormal invasive, migratory and proliferative properties. In accordance with the International Federation of Gynecology and Obstetrics (FIGO) guidelines, choriocarcinomas are diagnosed through detecting abnormally high concentrations of human chorionic gonadotropin (hCG) in maternal blood and sensitivity to a classical chemotherapeutic regimen (May et al., 2011; Soper, 2006) . For this reason, human placental choriocarcinomas have a relatively high cure rate as compared to other malignant tumors. However, 20% of patients who suffer from choriocarcinomas fail to survive due to delayed diagnosis or a recurrent tumor (Shen et al., 2015) . In addition, resistance to traditional chemotherapy using platinum-based agents and methotrexate, make it hard to cure the disease completely and this reduces survival rates of patients (Sakai et al., 1989; Zhao et al., 2014) . For this reason, it is necessary to develop a novel therapeutic for prevention and/or treatment of choriocarcinomas.
Mitochondria support respiration and production of energy as cytoplasmic organelles that are integral in sensing stress to enable cellular adaptation to diverse environments. Therefore, the mitochondria are regarded as hallmarks of cancers by their influence on protection from cell death, genomic instability, cancer-inducing inflammation, abnormal bioenergetics, oxidative stress and metastasis (Giampazolias and Tait, 2016; Vyas et al., 2016) . In response to apoptotic stimuli, proapoptotic proteins, including Bax and Bak, are activated by regulation of mitochondrial outer membrane permeabilization resulting in pore formation and cytochrome c release from the mitochondria into the cytosol, to induce cell death (Lopez and Tait, 2015; Sarosiek et al., 2013) . In addition, mitochondrial dysfunction is an essential event leading to oxidative stress and DNA damage in cancer cells and it is one of the targets for therapeutic agents (Zorov et al., 2014) . Consistent with this, mitochondrial function is important when investigating therapeutic interventions and screening new therapeutic agents for treatment of cancers.
Coumestrol, a major phytoestrogen in soy, is well known for multiple biological activities, including neuroprotective (Castro et al., 2014) , anti-inflammatory (You et al., 2017) , anti-aging (Park et al., 2015) , anti-adipogenesis (Jang et al., 2016) and anti-cancer properties.
Specifically, coumestrol induces programmed cell death in various cancer cells of the ovary (Lim et al., 2016b) , breast (Zafar et al., 2017) , prostate (Lim et al., 2017a) and colon (Lee et al., 2013b) . To suppress tumor cell growth, coumestrol regulates generation of ROS and cell senescence and it inhibits protein kinase casein kinase 2 (CK2) (Lee et al., 2013b , Zafar et al., 2016 . However, intracellular signaling mechanisms-mediated by coumestrol have not been elucidated in most cancer cells, and the functional role of coumestrol in gestational choriocarcinoma has not been reported.
In the present study, we investigated mechanisms whereby couemstrol regulates death of JAR and JEG3 human choriocarcinoma cells derived from human placental epithelial cells with similarities including secretion of chorionic gonadotropin and steroids. Effects of coumestrol on proliferation and apoptosis of choriocarcinoma cells were assessed in a dose-dependent manner. In addition, the effects of coumestrol on the metastatic capacity of JAR and JEG3 cells and their expression of VEGFA were determined. To identify intracellular signaling pathways leading to apoptosis induced by coumestrol, we used western blot analyses of proteins in the MAPK and mitochondriamediated apoptotic pathways. FurWe also determined responses of JAR and JEG3 cells to coumestrol with regard to mitochondrial dysfunction and production of ROS. Additionally, cytosolic and mitochondrial concentrations of Ca 2+ were calculated following disruption of calcium homeostasis by coumestrol. Overall, we identified coumestrolinduced cellular dysfunction and alterations to signal transduction pathways in two choriocarcinoma cell lines. ) and total ERK1/2, RSK1/RSK2/RSK3, JNK, c-Jun, Bax, Bak, Bcl-xL and Caspase-9, were purchased from Cell Signaling Technology. The antibody against TUBA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). N-acetyl-L-cysteine and 2-aminoethyl diphenylborinate were purchased from Sigma-Aldrich, Inc, and ruthenium red was from Abcam (Cambridge, UK).
Materials and Methods

Chemicals
Cell culture
The JAR and JEG3 cells that originated from placental choriocarcinoma epithelial cells were purchased from the ATCC and maintained in RPMI-1640 with 2.05 mM L-Glutamine (Cat No: SH30027.01, HyClone, Logan, UT, USA) for JAR cells and MEM (Cat No: 11095-080 , Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS) for JEG3 cells at 37°C in an incubator with an atmosphere of 5% CO 2 . For experiments, monolayer cultures of JAR and JEG3 cells were grown in culture medium to 70% confluence in 100-mm tissue culture dishes. Cells were serum starved for 24 h and then treated with coumestrol alone and also with inhibitors of cell signaling pathways.
Proliferation assay
Proliferation assays were conducted using Cell Proliferation ELISA, BrdU kit (Cat No. 11647229001, Roche, Indianapolis, IN, USA) according to the manufacturer's recommendations. Briefly, JAR (Passage No. 735) and JEG3 (Passage No. 132) cells were seeded in a 96-well plate, and incubated for 24 h in serum-free RPMI-1640 and MEM media, respectively. Cells were then treated with coumestrol alone or with various inhibitors of cell signaling in a final volume of 100 μL/well. After 48 h of incubation, 10 μM BrdU was added to the cell culture and the cells were incubated for an additional 2 h at 37°C. After labeling of cells with BrdU, the fixed cells were incubated with anti-BrdU-POD working solution for 90 min. The anti-BrdU-POD binds to BrdU incorporated in newly synthesized cellular DNA and these immune complexes were detected by their reaction with 3,3′,5,5′-tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product were quantified by measuring the absorbance at 370 nm and 492 nm using an enzyme-linked immunosorbent assay (ELISA) reader.
Immunofluorescence analysis
The effects of coumestrol on the expression of proliferating cell nuclear antigen (PCNA) were determined by immunofluorescence microscopy. JAR (Passage No: 735) and JEG3 (Passage No. 132) were probed with mouse anti-human monoclonal antibody to PCNA Santa Cruz Biotechnology) at a final dilution of 1:100 (2 μg/mL). They were then incubated with goat anti-mouse IgG Alexa 488 (Cat No. A-11001, Invitrogen, Carlsbad, CA, USA) at a 1:200 dilution for 1 h at room temperature. The negative control involved replacement of the primary antibody to PCNA with purified nonimmune mouse immunoglobulin G (IgG) at the same final concentration. Cells were then washed using 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) and overlaid with 4′,6-diamidino-2-phenylindole (DAPI). For each primary antibody, images were captured using a LSM710 (Carl Zeiss, Thornwood, NY, USA) confocal microscope. JAR (Passage No: 736) and JEG3 (Passage No. 133) cells (3 × 10 4 cells per 300 μL) were seeded in confocal dishes (Cat No: 100350, SPL Life Science, Republic of Korea) and incubated for 24 h in serum-free medium. Cells were then treated with 50 μM coumestrol for 48 h at 37°C in a CO 2 incubator. After incubation, the cells were air dried and fixed in 4% paraformaldehyde in PBS for 1 h at room temperature. The cells were rinsed with PBS briefly and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Then, the cells were subjected to TUNEL (terminal deoxynucleotidyl transferase dNTP nick end labeling) staining mixture using the In-situ Cell Death Detection kit, TMR red (Roche) for 1 h at 37°C in the dark. Cells were then washed with PBS and overlaid with DAPI. Fluorescence was detected using a LSM710 (Carl Zeiss) confocal microscope.
TUNEL assay
Determination of apoptosis by annexin V and propidium iodide staining 
Western blot analysis
Concentrations of protein in whole-cell extracts from JAR (Passage No: 737) and JEG3 (Passage No. 133) cells in response to each treatment were determined using the Bradford protein assay (Bio-Rad Hercules, CA, USA) with BSA as the standard. Proteins were denatured, separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose. Blots were developed using enhanced chemiluminescence detection (SuperSignal West Pico, Pierce, Rockford, IL, USA) and quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light using a ChemiDoc EQ system and Quantity One software (Bio-Rad, Hercules, CA, USA). Immunoreactive proteins were detected using goat anti-rabbit polyclonal antibodies against phosphorylated and total proteins at a 1:1000 dilution separated using 10% SDS/ PAGE. As a loading control, total proteins were used to normalize the results from detection of proteins by western blotting. All antibodies were from Cell Signaling Technology. Multiple exposures of each western blot were performed to ensure linearity of chemiluminescenct signals. These experiments were performed in triplicate.
JC-1 mitochondrial membrane potential assay
Changes in JC-1 mitochondrial membrane potential (MMP) were determined using a Mitochondria Staining kit (Cat No: CS0390, Sigma-Aldrich). JAR (Passage No: 736) and JEG3 (Passage No. 133) (5 × 10 5 cells) were seeded in 6-well plates and incubated for 24 h in serum-free medium to 70% confluency. Then, cells were treated with coumestrol in a dose-dependent manner for 48 h at 37°C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells were detached with trypsin-EDTA. The cells were collected by centrifugation and resuspended in staining solution that included 200 × JC-1 in 1× staining buffer and incubated at 37°C in a CO 2 incubator for 20 min. The stained cells were collected by centrifugation, and washed once with 1 × JC-1 staining buffer. After washing, the cell suspension was centrifuged once more and then the cells were resuspended in 1 mL staining buffer. Fluorescence intensity was analyzed using FACSCalibur (BD Biosciences).
Determination of cellular ROS
Intracellular ROS production was estimated based on the conversion of 2′, 
Determination of intracellular GSH levels
The GSH-Glo™ Glutathione Assay (Promega, Madison, USA) was used to measure glutathione (GSH) levels in cells according to the manufacturer's recommendations. Briefly, JAR (Passage No: 736) and JEG3 (Passage No. 132) were seeded in 96-well plates and treated with coumestrol in a dosedependent manner for 2 h at 37°C in a CO 2 incubator. The 1 × GSHGlo™ reagent was prepared with same volume of luciferin-NT substrate and glutathione S-transferase diluted in reaction buffer, and incubated for 30 min at room temperature. Reconstituted luciferin detection reagent was added to each well and the luminescence was measured using multidetection microplate reader (HIDEX).
Lipid peroxidation assay
Click-iT lipid peroxidation imaging kit (Invitrogen) was used according to the manufacturer's recommendation. Briefly, JAR (Passage No: 736) and JEG3 (Passage No. 133) cells (3 × 10 4 cells per 300 μL) were seeded in confocal dishes and treated with 50 μM coumestrol and 50 μM linoleamide alkyne (LAA) for 2 h at 37°C in a CO 2 incubator. After cell fixation (3.7% formaldehyde) and permeabilization (0.5% Triton X-100), the nucleophilic side chains of proteins modified by LAA oxidation were labeled by Alex Fluor 488 Azide for 30 min at room temperature. Fluorescence was detected using a LSM710 (Carl Zeiss) confocal microscope. were seeded in 6-well plates and incubated for 24 h in serum-free medium until they reached 70-80% confluency. Then the cells were treated with coumestrol, 2-aminoethoxydiphenyl borate (2-APB, Sigma), and 1,2-bis(oaminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA-AM, Santa Cruz) for 48 h at 37°C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells were detached with trypsin-EDTA. The cells were collected by centrifugation. Collected cells were resuspended in 3 μM Fluo-4 (Invitrogen) and incubated at 37°C in a CO 2 incubator for 20 min. The stained cells were washed with PBS. Fluorescent intensity was analyzed using a flow cytometer (BD Bioscience). were seeded in 6-well plates and incubated for 24 h in serum-free medium until they were at 70-80% confluency. Then cells were treated with coumestrol, 2-APB (Sigma) and BAPTA-AM (Santa Cruz) for 48 h at 37°C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells were detached with trypsin-EDTA. The cells were collected by centrifugation. Collected cells were resuspended in 3 μM Rhod-2 AM (Invitrogen) diluted in Hank's Balanced Salt Solution (HBSS, Gibco) and incubated at 4°C for 30 min. The stained cells were washed with HBSS. Fluorescent intensity was analyzed using a flow cytometer (BD Bioscience). For microscopic imaging, JAR and JEG3 cells (3 × 10 4 cells) were seeded on confocal dishes and then incubated for 24 h in serum-free medium. Cells were then treated with coumestrol, 2-APB, and BAPTA-AM for 48 h at 37°C in a CO 2 incubator. After incubation, the cells were stained with 200 nM mitotracker (Invitrogen) diluted in HBSS for 30 min at 37°C. Then the cells were washed with HBSS followed by Rhod-2 AM staining for 30 min at 4°C. Cells were then washed with HBSS and overlaid with DAPI. Fluorescence was detected using a LSM710 (Carl Zeiss) confocal microscope.
Measurement of intracellular free Ca
Statistical analysis
Data for proliferation assays and western blot analyses were subjected to analysis of variance (ANOVA) according to the general linear model (PROC-GLM) of the SAS program (SAS Institute, Cary, NC, USA) to determine significant effects of treatment on proliferation or signal transduction pathways for JAR and JEG3 cells. Differences with a probability value of P < 0.05 were considered statistically significant. Data are presented as mean ± SEM unless otherwise stated.
Results
Inhibitory effects of coumestrol on proliferation of choriocarcinoma cells
To determine cytotoxicity of coumestrol against choriocarcinoma cells, proliferation of JAR and JEG3 cells was analyzed in a dose-dependent manner (0, 5, 10, 20, 50 and 100 μM) (Fig. 1A ). There was a dosedependent decrease in proliferation of JAR and JEG3 cells as the concentration of coumestrol increased. Cell proliferation decreased more than 40% (P < 0.01) at 50 μM coumestrol for JAR cells, and approximately 34% at 100 μM coumestrol for JEG3 cells (P < 0.05). Consistent with these results, PCNA was strongly expressed in the non-treated JAR and JEG3 cells whereas its expression was decreased significantly in coumestrol-treated choriocarcinoma cells (Fig. 1B) . Cells treated with 100 μM coumestrol were easily floated off the culture dish during the immunofluorescence analysis for PCNA, indicating toxicity; therefore, we used 50 μM coumestrol in all subsequent experiments. These results indicate that 50 μM coumestrol reduces proliferation of choriocarcinoma cells, but decreases viability at 100 μM.
Apoptotic effects of coumestrol on choriocarcinoma cells
To demonstrate programmed cell death in choriocarcinoma cells by coumestrol, we performed TUNEL assays as illustrated in Fig. 2A . In normal state, DNA fragmentation (red fluorescence) which is a hallmark of apoptosis was not detected using the TUNEL assay. However, DNA fragmentation occurred in the nuclei of both JAR and JEG3 cells in response to 50 μM coumestrol. In addition, we quantitated the apoptotic cells by staining coumestrol-treated choriocarcinoma cells with annexin V and PI solution (Fig. 2B) . With increasing concentrations of coumestrol, there was an increase in apoptotic JAR and JEG3 cells. Specifically, there was a 1.9-fold increase in apoptotic JAR cells and a 1.8-fold increase in apoptotic JEG3 cells at 100 μM coumestrol compared with non-treated choriocarcinoma cells. Thus, coumestrol induces apoptosis of choriocarcinoma cells.
Blockage of metastatic ability of coumestrol against choriocarcinoma cells
To investigate effects of coumestrol on metastasis of choriocarcinoma cells, migration of JAR and JEG3 cells was analyzed using a Transwell migration assay (Fig. 3A) . Migrating cells stained by hematoxylin and expressing purple dots were numerous for transmembranes incubated with untreated JAR and JEG3 cells. On the other hand, treatment of the JAR and JEG3 cells with 50 μM coumestrol decreased the number of migrating cells by more than 70% (P < 0.001) compared with nontreated control cells. In addition to migration of tumor cells, angiogenesis also commonly induces metastasis in various cancers. Therefore, we analyzed culture medium for VEGFA, a major angiogenic factor, and found that coumestrol decreased concentrations of VEGFA by approximately 68% (P < 0.001) in JAR cells and 58% (P < 0.001) in JEG3 cells (Fig. 3B) . These results indicate that coumestrol suppresses metastatic properties of choriocarcinoma cells.
Coumestrol-mediated ERK1/2 and JNK MAPK pathways in choriocarcinoma cells
To determine coumestrol-mediated signal transduction pathways, western blot analyses were conducted in a dose-(0, 10, 20 and 50 μM) and in a time-(0, 5, 15, 30, 60 and 120 min) dependent manner using a concentration of 50 μM coumestrol (Fig. 4) . Phosphorylation of ERK1/2, P90RSK, JNK and c-Jun proteins increased in response to a high dose of coumestrol in JAR and JEG3 cells (Fig. 4A-D) . Among them, ERK1/2 and P90RSK proteins were rapidly phosphorylated in JEG3 cells within 15 min whereas these proteins were more slowly activated in JAR cells in response to coumestrol ( Fig. 4E and F) . In addition, the phosphorylation of JNK was evident at 15 min post-treatment with coumestrol and maintained until 60 min post-treatment in JAR and JEG3 cells (Fig. 4G) . Phosphorylation of c-Jun, increased gradually in choriocarcinoma cells with increasing times of incubation with coumestrol (Fig. 4H) . We next determined the effects of inhibiting ERK1/2 and JNK MAPK pathways, using pharmacological inhibitors, on the proliferation of choriocarcinoma cells (Fig. 5) . Treatment with U0126 (an ERK1/2 inhibitor) or SP600125 (a JNK inhibitor) decreased cell viability by approximately 61% (P < 0.001) and 46% (P < 0.01), respectively, in JAR cells (Fig. 5A) . The combination of coumestrol and U0126 or SP600125 acted synergistically to suppress proliferation in JAR cells as compared to individual effects of each inhibitor. Cell proliferation was reduced 85% (P < 0.001) and 76% (P < 0.001) for cells treated with coumestrol plus U0126 and coumestrol plus SP600125, respectively. Moreover, U0126 and coumestrol together reduced proliferation of JEG3 cells by 53% (P < 0.01) compared to nontreated control cells whereas U0126 alone reduced proliferation in JEG3 cells by 38% (P < 0.05) (Fig. 5B) . However, there was no synergistic effect of coumestrol with SP600125 on proliferation of JEG3 cells. To further investigate crosstalk between ERK1/2 and JNK pathways, the activated target protein kinases were analyzed in response to coumestrol with U0126 or SP600125 by western blot analysis (Fig. 6) . The increase in phosphorylation of ERK1/2 by coumestrol was suppressed in U0126 treated choriocarcinoma cells (Fig. 6A) . Phosphorylated P90RSK in JAR cells was inhibited by a combination of coumestrol and U0126 or SP600125, but only slightly reduced in JEG3 cells treated with coumestrol and U0126 (Fig. 6B) . Coumestrol-induced JNK phosphorylation was inhibited by SP600125 (Fig. 6C) , however, JNK phosphorylation in JEG3 cells increased in response to coumestrol and U0126. Consistent with JNK phosphorylation, coumestrol-activated phosphorylation of c-Jun was completely inhibited by SP600125 in JAR and JEG3 cells (Fig. 6D) . These results indicate that coumestrol interacts with ERK1/2 and JNK signal transduction to exert chemotherapeutic effects on human choriocarcinoma cells.
Mitochondria-mediated apoptosis and production of reactive species oxygen by coumestrol
To investigate the function of mitochondria in mediating coumestrolinduced programmed cell death, we determined mitochondrial membrane potential (MMP) using flow cytometry for detecting JC-1 stained-choriocarcinoma cells. Coumestrol increased depolarization of MMP in a dose-dependent manner (P < 0.05) (Fig. 7A) . Among mitochondrial-mediated apoptotic proteins, the expression of proapoptotic proteins Bax and Bak increased in JAR and JEG3 cells in response to coumestrol in a dose-dependent manner. In addition, the expression of cytochrome c protein was activated by an increase in the concentrations of coumestrol used to treat JAR and JEG3 cells. Also, cleavage of caspase-9 and caspase-3 was activated by coumestrol in both JAR and JEG3 cells (Fig. 7B) . These results indicate that coumestrol-induced apoptosis in choriocarcinoma cells involves mitochondrial dysfunction. We also determined intracellular ROS levels, which are associated with diverse diseases by disruption of homeostasis within cellular organelles. As illustrated in Fig. 7C , coumestrol-induced production of ROS in JAR and JEG3 cells (P < 0.001), while reducing intracellular glutathione (GST) by 14% and 32% (P < 0.01) in JAR and JEG3 cells, respectively (Fig. 7D) . Further, we determined lipid peroxidation since oxidative degradation of cellular lipids is initiated by increasing ROS (Fig. 7E) . Coumestrol strongly induced peroxidation of membrane lipids in the choriocarcinoma cell lines. Taken together, these results indicate that coumestrol causes for 2 h at 37°C in a CO 2 incubator and then proteins used in western blot analyses were collected using a lysis buffer. (E-H) Changes in the abundances of phosphorylated ERK1/2 (E), JNK (F), P90RSK (G) and c-Jun (H) in response to 50 μM coumestrol were determined in a time-dependent manner (0, 5, 15, 30, 60 and 120 min). Immunoblots were captured to calculate the normalized values which are presented in the graph as estimates of the abundances of phosphorylated proteins relative to total proteins. An asterisk indicates an effect of treatment (*P < 0.05).
mitochondrial dysfunction and ROS generation to increase apoptosis of choriocarcinoma cells.
Cytoplasmic Ca 2+ release and mitochondrial influx of Ca 2+ induced by coumestrol
To investigate more detailed mechanisms of coumestrol-activated programmed cell death within mitochondria, we determined intracellular Ca 2+ levels which act as a signal transducer to stimulate mitochondrial function (Fig. 8) . Flow cytometry analysis using Fluo-3 (a cell-permeable Ca 2+ indicator dye) showed that coumestrol increased Ca 2+ in the cytosol levels with maximum effects at 50 μM coumestrol (P < 0.001). In JEG3 cells, cytosolic Ca 2+ increased 177% (P < 0.05) at 20 μM coumestrol, but tended to decrease at 50 and 100 μM coumestrol ( Figure 8A ). In addition, flow cytometry using Rhod-2 (an indicator dye for mitochondrial Ca
2+
) indicated that coumestrol also increased Ca 2+ in mitochondria in a dose-dependent manner when JAR cells were treated with 0 to 50 μM coumestrol (P < 0.05), however, in JEG3 cells Ca 2+ levels in mitochondria increased only slightly at 20 μM coumestrol ( Figure 8B ). Consistent with these results, we determined effects of 2-APB (an antagonist of IP3 receptor) and BAPA-AM (an intracellular Ca 2+ chelator) on coumestrol-induced changes in intracellular Ca 2+ in the choriocarcinoma cell lines ( Figure 8C and 8D). Increases in cytosolic and mitochondrial Ca 2+ in response to coumestrol decreased in JAR cells treated with 2-APB and BAPA-AM. In addition, coumestrol-induced increases in cytosolic and mitochondrial Ca 2+ were reduced in JEG3 cells in response to increasing doses of 2-APB and 1 μM BAPA-AM. We further visualized mitochondria-specific calcium using confocal microscopy. Although non-treated JAR and JEG3 cells expressed weak red fluorescence, coumestrol-treated cells showed strong intensity of Rhod-2 ( Figure 8E ). However, the increased expression of Rhod-2 was inhibited by a combination of coumestrol and 2-APB or BAPTA-AM in both JAR and JEG3 cells. These results showed that coumestrol-induced apoptosis in choriocarcinoma cells involves increases in intracellular concentrations of Ca
.
Effects of blocking effects of intracellular Ca
2+ on MMP and viability of choriocarcinoma cells
Next, we demonstrated inhibitory roles of cytosolic and mitochondrial Ca 2+ levels on mitochondrial membrane potential (MMP) and viability of coumestrol-treated choriocarcinoma cells ( Figure 9 ). As shown in Figure 9A , a 39% increases in loss of MMP (P < 0.05) by coumestrol was reversed (P < 0.01) in JAR cells treated with a combination of coumestrol and 2-APB (0.5 μM and 1 μM) or BAPTA-AM (1 μM and 2 μM) ( Figure 9A ). Although the loss of MMP induced by coumestrol (71%, P < 0.05) was decreased by a combination of coumestrol and 2-APB in JEG3 cells, BAPTA-AM did alter the loss of MMP induced by coumestrol. Moreover, the decrease in proliferation of JAR cells was only slightly reversed by a combination of coumestrol and either 2-APB or BAPTA-AM whereas 2-APB or BAPTA-AM alone did not influence cell proliferation ( Figure 9B ). Decreased viability of JEG3 cells in response to coumestrol was not recovered significantly in response to coumestrol and 1 μM BAPTA-AM. In addition to the effects of inhibition of IP3 receptors and intracellular Ca 2+ levels, we determined the effects of inhibition of ERK1/2 and JNK MAPK pathways on depolarization of MMP and concentrations of Ca 2+ in mitochondria (see Figures 9C and D) . A combination of coumestrol with U0126 or SP600125 increased the loss of MMP as compared to coumestrol alone-treated JAR cells ( Figure 9C ), while treatment of JAR cells with U0126 alone induced the loss of MMP approximately by 53-fold (P < 0.001) as compared to non-treated cells. In JEG3 cells, the loss of MMP was increased by the combination of coumestrol and U0126 or U0126 alone as compared to non-treated and coumestrol-treated JEG3 cells whereas the additional treatment of coumesterol-treated cells with SP600125 did not affect loss of MMP ( Figure 9C ). Then we analyzed the effects of ERK1/2 and JNK inhibitors on mitochondrial Ca 2+ concentrations in JAR and JEG3 cells ( Figure 9D ).
Mitochondrial Ca 2+ concentrations were increased more in response to a combination of coumestrol with U0126 or SP600125 in JAR and JEG3 cells compared to the coumestrol only treated cells. Taken together, the effects of coumestrol on intracellular Ca 2+ are mediated by IP 3 R and calcium chelators to effect changes in the transmembrane potential of the mitochondria and proliferation of choriocarcinoma cells. Also inhibition of ERK1/2 and JNK pathways altered depolarization of MMP and mitochondrial Ca 2+ levels. , for 48 h. Cell numbers were estimated using the cell proliferation assay, and data are presented as percentages relative to nontreated control cells (100%). All quantitative data are presented as the least-squares method (LSM) with overall standard error of the mean (SEM). Asterisks indicate significant differences compared to non-treated control (*P < 0.05, **P < 0.01 and ***P < 0.001).
Discussion
Results of present study indicate that a functional role of coumestrol is to inhibit proliferation and invasiveness, while inducing apoptosis of JAR and JEG3 choriocarcinoma cells. In addition, we found that coumestrol mediates it action via interaction with cell signaling proteins within the MAPK and intrinsic pathways. In addition, coumestrol was discovered to mediate effects via mitochondrial-regulated processes including production of ROS, decreasing GSH and altering transmembrane potential and Ca 2+ homeostasis in JAR and JEG3 cells.
Moreover, we confirmed the inhibitory effects of coumestrol on intracellular Ca 2+ which affected proliferation and mitochondrial membrane potentials in choriocarcinoma cells. Taken together, our results provide evidence for the working model whereby coumestrol controls the progression of human placental choriocarcinoma cells toward proliferation and metastasis (see Figure 10) . Natural products and their derivatives that are derived from animals, plants, insects and microbes are novel therapeutic agents against diverse human diseases (Mishra and Tiwari, 2011) . For instances, capsaicin, an active component of chilli peppers, induces a burning sensation in skin through its interaction with the ion channel receptor vanilloid receptor subtype 1; therefore, Qutenza ® was developed for prevention of neuropathic pain and approved by FDA in 2009 (Kissin, 2008; Mishra and Tiwari, 2011) . For anti-cancer effects, camptothecin, a quinolone based cytotoxic alkaloid isolated from the bark and stem of Camptotheca acuminana, was developed and marketed as Karenitecin ® for treatment of advanced ovarian cancer and melanoma by inhibiting topoiosomerase I (Daud et al., 2009; Van Hattum et al., 2002) . Consistent with these results, development of novel natural compounds as therapeutics is required to overcome resistance to currently used chemotherapeutics for treatment of various cancers. Moreover, due to the severe toxicity of traditional chemotherapeutics, there is a demand for efficient chemotherapeutic agents with fewer side-effects for treatment of cancers. In particular, compounds in medicinal plants may improve efficiency in the treatment of reproductive disorders. For instance, chrysophanic acid, a derivative of anthraquinoens, decreases testosterone-dependent benign prostatic hyperplasia through regulating 5α-reductase and ERK1/2 pathways (Youn et al., 2017) . In addition, curcumin suppresses endometriotic epithelial cells via a decrease in estrogen levels (Zhang et al., 2013) . Moreover, delphinidin, one of the anthocyanins found in red cabbage, sweet potatoes and berries, inhibits proliferation of ovarian cancer cells by blockage of PI3K and ERK1/2 MAPK pathways (Lim et al., 2016c) . Furthermore, phytoestrogens including daidzein, geinstein, coumestrol and resveratrol that increases estrogen response element dependent transcriptional activity in the same manner as estradiol, also increase apoptosis by p53 transcriptional activity in estrogen receptor-positive breast cancer cells (Bilal et al., 2014; Sakamoto et al., 2010) . inhibitor (U0126) and a JNK inhibitor (SP600125) on coumestrol-activated phosphorylation of ERK1/2 (p-ERK1/2) (A), p-P90RSK (B), p-JNK (C) and p-c-Jun (D) proteins were determined by western blot analyses. Starved JAR and JEG3 cells were pre-incubated in serum-free medium with U0126 (10 μM) or SP600125 (10 μM) for 2 h and then treated with 50 μM coumestrol for 2 h. Immunoblots were captured to calculate the normalized values presented in the graph by estimating the abundances of phosphorylated proteins relative to total proteins. Asterisks indicate significant differences compared to non-treated control (*P < 0.05, **P < 0.01 and ***P < 0.001).
Consistent with previous studies in reproductive medicine, results of the present study revealed that coumestrol has significant beneficial effects to prevent progression of choriocarcinomas. Coumestrol-induced apoptosis in the choriocarcinoma cells and reduced their proliferation and invasiveness. We then demonstrated that coumestrol interacted with PI3K/AKT and MAPK signaling molecules which are responsible in a variety of cancerous cells for induction of cell death. We previously reported that apoptotic effects of other natural compounds on JAR and The effects of coumestrol on glutathione (GSH) levels in choriocarcinoma cells. The amount of GSH present in the cells is proportional to luminescence generated by reaction with firefly luciferase. (E) Lipid peroxidation of cellular membranes was visualized using confocal microscopy. The intensity of green fluorescence (Alexa 488 azide staining) indicated oxidation of linoleic acid. Cell nuclei were counterstained with DAPI (blue). The scale bar represents 40 μm (first and third horizontal panels) and 20 μm (second and fourth horizontal panels). Asterisks indicate significant differences compared to non-treated control cells (*P < 0.05, **P < 0.01 and ***P < 0.001).
JEG3 cells are regulated by the PI3K and/or MAPK signaling pathways (Lim et al., 2016a (Lim et al., , 2016d (Lim et al., , 2017b . Similarly, coumestrol interacts with the ERK1/2 MAPK and JNK MAPK pathways. Those results were confirmed by demonstrating that coumestrol-induced cell death was enhanced by SP600125 which blocks JNK and by U0126 which inhibits ERK1/2 cell signaling. The coumestrol-induced decrease in viability of JEG3 cells was Asterisks indicate significant differences compared to non-treated control (*P < 0.05, **P < 0.01 and ***P < 0.001).
enhanced when combined with U0126 whereas SP600125 did not further affect cell proliferation. Consistent with our results, Shih et al. (2016) reported that epigallocatechin gallate from green tea significantly increases phosphorylation of ERK1/2, P38 and AMPK in JAR, JEG3 and BeWo cells and decreased cell proliferation (Shih et al., 2016) . ROSmediated JNK/p62 signaling regulates ER-stress-induced cell death in methotrexate-resistant choriocarcinoma cells (Shen et al., 2015) . Furthermore, the CXCL12-CXCR7 interaction activates ERK1/2 and AKT signal transduction in choriocarcinoma cells (Tripathi et al., 2014) . Also, vitamin D increases ERK1/2 MAPK signaling in JEG3 cells (Pospechova et al., 2009) . Taken together, these results reveal that coumestrol-mediated ERK1/2 MAPK and JNK MAPK pathways are integral for apoptosis of human placental choriocarcinoma cells. Initiation of programmed cell death is tightly controlled by the intrinsic pathway from mitochondria. As for mitochondrial cell death susceptibility, the Bcl-2 family includes anti-(Bcl-2, Bcl-xL, Bcl-w and for control cells. The asterisks indicate an effect of treatment (*P < 0.05, **P < 0.01 and ***P < 0.001).
Mcl-1) and pro-(Bax, Bak, BIM, BID and PUMA) apoptotoc proteins which share one or several Bcl-2 homology (BH) domains (BH1-4). Because Bax and Bak proteins include the BH3 domain, they are stimulated only by BH3-binding proteins activated through apoptotic stimuli including chemotherapy (Lopez and Tait, 2015) . In addition, the both of those pro-apoptotic proteins permeabilize the mitochondrial outer membrane leading to the release cytochrome c into the cytosol and activation of cysteine proteases, referred to as caspases, by inducing conformational changes responsible for their translocation, integration and oligomerization (George et al., 2010; Schinzel et al., 2004; Wolter et al., 1997) . Results of the present study indicated that coumestrol increased depolarization of MMP and the pro-apoptotic proteins (Bax and Bak) in a dose-dependent manner in JAR and JEG3 cells. In addition, caspase-9 and caspase-3 were activated in response to coumestrol treatment in both choriocarcinoma cell lines. These results indicate that coumestrol stimulates mitochondria-mediated cell death in choriocarcinoma cells.
Regarding mitochondria-mediated cell death, excessive ROS production is closely associated with mitochondrial DNA mutations, aging and cell death in a variety of pathologies such as cancers, chronic inflammatory diseases and neurodegenerative diseases (Orrenius, 2007) . Intracellular ROS production also causes a depletion of GSH and lipid peroxidation. Because GSH is a major antioxidant in cells to control redox status, GSH depletion is considered as an early indicator of the progression toward apoptosis due to intra-and extracellular stress (Franco and Cidlowski, 2009 ). In addition, ROS-induced lipid peroxidation changes integral mitochondrial functions including respiration, inner membrane barrier properties, maintenance of MMP and mitochondrial Ca 2+ homeostasis (Barrera, 2012; Chen et al., 1995) . To enhance cancer therapy, a number of dietary and medicinal plants have been researched as anti-oxidants or a pro-oxidant. For example, quercetin induces ROS production to stimulate apoptosis of human choriocarcinoma cells whereas quercetin reduces ROS generation and increases motility of human fibrosarcoma cells (Lee et al., 2013a , Lim et al., 2017b . Cancer cells commonly have high intracellular ROS levels compared to normal cells and oxidative stress may induce adaptive stress responses for maintaining the viability of cancer cells that have an increase in production of ROS. However, the excessive ROS production in cancer cells in response to natural compounds such as quercetin, curcumin and coumestrol promotes apoptotic events (Gibellini et al., 2010; Poljsak et al., 2013) . In addition, sulforaphane in broccoli induces programmed cell death in prostate cancer cells by ROS generation and depletion of GSH leading to mitochondria-induced apoptosis (Singh et al., 2005) . Moreover, withaferin A, a major constituent of Withania In addition, coumestereol induces ROS production and increases in cytosolic and mitochondrial Ca 2+ from mitochondria due to permeabilization of the mitochondrial membrane. Then, the release of Ca 2+ from the endoplasmic reticulum into the cytosol further stimulates permeabilization of the mitochondrial membrane and accelerates caspase-dependent intrinsic apoptosis by activating pro-apoptotic proteins (Bax and Bak), cleavage of caspase-9 and caspase-3 and secretion of cytochrome c. Collectively, coumestrol induces apoptosis of human placental choriocarcinoma cells through mechanisms that involve mitochondria-mediated processes and MAPK cell signaling pathways.
somnifera known as a steroidal lactone, induces ROS-dependent apoptosis in breast cancer and leukemia (Hahm et al., 2011; Malik et al., 2007) . Results of the present study revealed that coumestrol activates generation of ROS which decreases GSH and induces lipid peroxidation and results in apoptosis of choriocarcinoma cells. These results indicate that coumestrol induces excessive ROS production with respect to mitochondria-dependent apoptotic pathways in choriocarcinoma cells. Mitochondrial permeability that occurs in response to various chemicals and radicals is closely related to Ca 2+ linked process following cell injury (Lemasters et al., 2009) . The Ca 2+ levels are activated by phospholipase C which releases inositol triphosphate to mobilize Ca 2+ from the endoplasmic reticulum in response to environmental stimuli (Berridge, 2009; Byrne et al., 1999) . Additionally the stress-stimulated influx of Ca 2+ into the cytosol results in its accumulation in mitochondria and oxidative phosphorylation promotes apoptosis that is dependent on Ca 2+ -mediating signaling. For this reason, understanding the remodeling of calcium homeostasis is important in cancer research. In hepatomas, quercetin increases intracellular concentrations of Ca 2+ and autophagy which inhibits progression of cancerous cells (Cui et al., 2015) . And curcumin, a yellow pigment from Curcuma longa, impairs Ca 2+ homeostasis leading to apoptosis by inhibition of sarco/endoplasmic reticulum calcium ATPase in ovarian cancer whereas it does not affect surface epithelial cells of the ovary (Seo et al., 2016 were suppressed by 2-APB (an antagonist of IP 3 R) and BAPTA-AM (an extracellular Ca 2+ chelator). In addition, the combination of coumestrol and 2-APB or BAPTA-AM effectively allowed the cells to recover from the coumestrol-induced inhibition of proliferation and mitochondrial membrane potentials. These results indicate that disruption of intracellular Ca 2+ homeostasis contributes to mitochondriamediated damage to choriocarcinoma cells.
In conclusion, the results of present study indicate that coumestrol inhibits proliferation and invasiveness, and induces apoptosis in JAR and JEG3 choriocarcinoma cells. The apoptotic effects of coumestrol were mediated via ERK1/2 MAPK and JNK MAPK signal transduction. Coumestrol also induced excessive ROS production, loss of mitochondrial integrity and changes of intracellular Ca 2+ leading to mitochondrial dysfunction. The disruption of intracellular Ca 2+ homeostasis also affected cell proliferation and mitochondrial integrity in choriocarcinoma cells. Collectively, coumestrol may be a novel chemotherapeutic agent for treatment of choriocarcinomas by regulating ERK1/2 and JNK signaling and mitochondria-mediated functions, to impair progression of the cancer.
